# Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

> **NCT05401357** · PHASE3 · RECRUITING · sponsor: **Amneal Pharmaceuticals, LLC** · enrollment: 168 (estimated)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** Test - Bimatoprost 0.01% Ophthalmic Solution
- **DRUG:** Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)

## Key facts

- **NCT ID:** NCT05401357
- **Lead sponsor:** Amneal Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-29
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2022-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05401357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05401357, "Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05401357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*